<span item_type="fundamental" item_id="2826ae5e26e39dd4f460c370283e8fcb" counter_id="ST/US/CABA" env="prod"></span><span item_type="announcement" item_id="648238233696076289" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.39, beating the estimate of USD -0.4.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -44.74 M.</p><p></p><h3>First Quarter 2026 Financial Results</h3><h4>Operating Expenses</h4><ul><li>Research and development expenses for Cabaletta Bio, Inc. were $37.4 million for the three months ended March 31, 2026, an increase from $29.0 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>General and administrative expenses were $6.9 million for the three months ended March 31, 2026, a decrease from $8.1 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Total operating expenses amounted to $44.3 million for the first quarter of 2026, compared to $37.1 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li></ul><h4>Profitability</h4><ul><li>Loss from operations was -$44.3 million for the three months ended March 31, 2026, compared to -$37.1 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Interest income was $1.1 million for the first quarter of 2026, a decrease from $1.5 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Interest expense was -$0.6 million for the first quarter of 2026, compared to -$0.3 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Other income, net was $0.3 million for the first quarter of 2026, with no reported amount for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>The net loss for the three months ended March 31, 2026, was -$43.5 million, compared to -$35.9 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li></ul><h4>Balance Sheet Data</h4><ul><li>Cash, cash equivalents and short-term investments for Cabaletta Bio, Inc. were $116.6 million as of March 31, 2026, down from $133.6 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Total assets were $148.1 million as of March 31, 2026, compared to $165.1 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Total liabilities were $44.8 million as of March 31, 2026, a decrease from $53.0 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li><li>Total stockholders’ equity was $103.3 million as of March 31, 2026, compared to $112.1 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li></ul><h4>Capital Activities</h4><ul><li>In May 2026, Cabaletta Bio, Inc. closed an underwritten registered direct offering, raising approximately $150 million in gross proceeds.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></li></ul><h4>Outlook / Guidance</h4><p>Cabaletta Bio, Inc. expects its cash position as of March 31, 2026, combined with the cash from the May 2026 registered direct offering, to fund its operating plan into mid-2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span> The company anticipates its first Biologics License Application (BLA) submission for rese-cel in myositis in 2027, supported by data from the registrational RESET-Myositis trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span> Cabaletta Bio, Inc. also plans to announce a second pivotal indication after presenting complete Phase <sup>1</sup>⁄<sub>2</sub> lupus and scleroderma data during the June 2026 EULAR Congress, and expects to report longer-term, PC-free rese-cel data in the second half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-ex99_1.htm"></span></p>

Cabaletta Bio | 8-K: FY2026 Q1 Revenue: USD 0